



Tandem Diabetes Care to Announce First Quarter 2022 Financial Results on May 4, 2022

April 11, 2022

SAN DIEGO--(BUSINESS WIRE)--Apr. 11, 2022-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2022 results after the financial markets close on Wednesday, May 4, 2022. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2022 financial and operating results.

Conference Call/Webcast Details:

Date: May 4, 2022

Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)

Toll Free Dial-In Number: (855) 427-4396

International Dial-In Number: (484) 756-4261

Conference ID: 2354706

Webcast Link: <https://edge.media-server.com/mmc/p/i8hq38ud>

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care's Investor Center website located at <http://investor.tandemdiabetes.com> in the "Events & Presentations" section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company's human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #t:slimX2, and \$TNDM.

Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.

Follow Tandem Diabetes Care on LinkedIn at <https://www.linkedin.com/company/tandemdiabetes>.



View source version on businesswire.com: <https://www.businesswire.com/news/home/20220411005620/en/>

Media Contact:

Steve Sabicer

714-907-6264

ssabicer@thesabicergroup.com

Investor Contact:

Susan Morrison

858-366-6900

IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.